================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): April 26, 2007
Anika Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
--------------------
Massachusetts 000-21326 04-314-5961
(State or other jurisdiction of Commission file number (I.R.S. Employer
incorporation or organization) Identification No.)
160 New Boston Street, Woburn, MA 01801
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code: 781-932-6616
(Former name or former address, if changed since last report)
--------------------
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|_| Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
================================================================================
Section 2--Financial Information
Item 2.02. Results of Operations and Financial Condition.
The following information, including the exhibit attached hereto, is intended to
be furnished and shall not be deemed "filed" for purposes of Section 18 of the
Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933 or the Exchange Act, except as
expressly set forth by specific reference in such filing.
On April 26, 2007, Anika Therapeutics, Inc. issued a press release announcing
its financial results for the first quarter ended March 31, 2007. The full text
of the press release is furnished as Exhibit 99.1 hereto and is incorporated
herein by reference.
Section 9--Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
99.1 Press Release of Anika Therapeutics, Inc. dated April 26, 2007.
[Remainder of page left blank intentionally]
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be filed on its behalf by the
undersigned hereunto duly authorized.
Anika Therapeutics, Inc.
Dated: April 26, 2007 By: /s/ Kevin W. Quinlan
---------------------------------
Kevin W. Quinlan
Chief Financial Officer
Exhibit Index
99.1 Press Release of Anika Therapeutics, Inc. dated April 26, 2007 .